Our Mission: To increase the world’s ability to discover cures
Leveraging massive amounts of biomedical data
Plex transforms how pharmaceutical and biotech teams discover targets, evaluate programs, and make critical R&D decisions — grounded in real scientific evidence, not AI guesswork.
Get a Free Report Request a Demo
QWhich targets can overcome EGFR inhibitor |
Searching the knowledge graph…
Extracting focal subgraph…
EGFRKRASTP53NSCLCErlotinibMETHER2T790MC797SSotorasibOsimertinibAdenoca.TKIPhase IIIPI3KTrastuzumabTargetsCompoundsDiseasesPathways
Plex Analysis
Example query: Which targets can overcome EGFR inhibitor resistance in NSCLC?
Plex queries billions of biomedical data points across genomics, proteomics, compound activity, and clinical trials using the Focal Graph knowledge graph.
Example result: Key resistance targets include MET amplification, KRAS G12C, and HER2/ERBB2 — with secondary mutations in EGFR T790M and C797S driving acquired resistance to first- and third-generation tyrosine kinase inhibitors (TKIs). Plex integrates genomic, proteomic, and Perturb-seq signatures to rank targets by evidence strength.
The Focal Graph visualizes relationships between targets (EGFR, KRAS, TP53, MET, HER2), compounds (Erlotinib, Sotorasib, Osimertinib, TKI, Trastuzumab), diseases (NSCLC, Adenocarcinoma), and pathways (T790M, C797S, PI3K) to surface evidence-backed insights for drug discovery.
Trusted by 40+ pharmaceutical and biotech discovery teams
Ask Plex
Ask any scientific question. Get evidence-backed answers.
Plex searches billions of data points across genomics, proteomics, clinical trials, and published literature to deliver structured, data-rich answers.
?Which targets are implicated in EGFR-resistant NSCLC??What biomarkers predict response to anti-PD1 therapy in melanoma??Evaluate TREM2 as a therapeutic target for Alzheimer's disease.
Plex Answer
Key resistance targets include MET amplification, KRAS G12C, and HER2/ERBB2 — with secondary mutations in EGFR T790M and C797S driving acquired resistance to first- and third-generation tyrosine kinase inhibitors (TKIs). Plex integrates genomic, proteomic, and Perturb-seq signatures to rank targets by evidence strength.
OncologyTarget IDResistance
The Platform
Scientific intelligence, not just search
Plex goes beyond literature retrieval. It integrates, scores, and structures scientific evidence into actionable intelligence for drug discovery decisions.
🔬
Knowledge Graph
Billions of data points from genomics, proteomics, clinical trials, and literature — structured and queryable.
📊
Evidence Scoring
Every answer is backed by quantified evidence across 7 evaluation dimensions with full source traceability.
🔒
Proprietary Data Safe
Integrate your internal experimental data under strict confidentiality — it never leaves your environment.
How It Works
From data to discovery in three steps
01
Ask a question
Pose any scientific question — from target identification to biomarker discovery. Plex understands both biological and chemical context.
02
Plex searches the knowledge graph
Billions of data points spanning biology and chemistry — genomics, proteomics, compound activity, and clinical data — are integrated and scored in real time.
03
Get structured, actionable answers
Receive evidence-backed results with confidence scores, source citations, and built-in chemical intelligence tooling for structure-aware analysis.
Why Plex
Plex is not a literature search tool
Plex is a knowledge graph with an LLM for data and databases used in biomedical research.
While other tools search published text, Plex queries structured biological and chemical datasets — genomics, proteomics, compound activity, clinical trials — to deliver answers grounded in real data, not summarized literature.
—Literature-Based LLMs
- Trained on text — searches literature, not data
- No access to structured scientific databases
- Generates plausible-sounding but unverifiable answers
- Cannot query genomic, proteomic, or chemical datasets
- No reproducibility — answers change with each query
vs
✓Plex: Data-First
- Built on billions of structured data points from biomedical databases
- Queries genomic, proteomic, clinical, and chemical datasets directly
- Every answer traceable to specific data sources and records
- Integrated chemical intelligence tooling for compound analysis
- Reproducible, evidence-scored outputs ready for R&D decisions
Built for Real Discovery
One platform, many use cases
From early-stage target identification to portfolio-level governance decisions.
Target Identification \ Discover novel therapeutic targets with multi-omics evidence integration.\ → Biomarker Discovery \ Identify predictive and prognostic biomarkers across patient populations.\ → Target Evaluation \ Score and compare targets across 7 evidence dimensions before committing capital.\ → For Scientists \ Accelerate hypothesis generation with structured, evidence-backed analysis.\ → For Developers \ Integrate Plex's knowledge graph into your computational pipelines.\ → For Executives \ Make faster, more confident portfolio decisions with structured evaluation.\ →
Scientific Outputs
Decision-ready deliverables, not just answers
Plex doesn’t just surface information — it structures it into the formats your team actually needs for governance and decision-making.
Target Evaluation Report
Structured assessment across 7 dimensions — biology, genetics, druggability, safety, clinical signal, competitive landscape, and proprietary data concordance.
Multi-omicsEvidence ScoringPDF Export
Biomarker Panel
Prioritized candidate biomarkers with predictive power estimates, validation status, and recommended assay strategies for clinical translation.
PredictivePrognosticCompanion Dx
Competitive Intelligence
Real-time landscape analysis of competing programs, MOA overlap, clinical trial status, and differentiation opportunities.
Pipeline TrackerPatent AnalysisMarket Signal
Ready to transform your drug discovery decisions?
See how Plex integrates your data, scores evidence, and delivers structured intelligence your team can act on.